Topic: central nervous system
After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.
The deal gives Sarepta exclusive licenses to four CNS targets plus an option to pay a further $42.5 million to add another four targets to the deal.
Biotech ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.
Armed with $44 million, Arkuda Therapeutics is going after a protein that plays a role in neuronal health and lysosomal function to treat dementia.
A small private biotech has raised a modest series B as it continues to test its idea that the memory-wasting disease can be beaten back by focusing o
As Flagship officially launches Cygnal, the startup is filling in some details, including how its tech works and where it wants to go beyond cancer
Ducharme rejoins Purdue at a time when it is trying to expand beyond the opioids that built but now threaten to sink its business.
Two years after it walked away from a Voyager Therapeutics-partnered Parkinson’s gene therapy, Sanofi Genzyme is at it again.
A Harvard-led team has built brain organoids that mimic the cell types and connections that every human brain has.
ArunA Bio CEO Mark Sirgo and Chief Scientific Officer Steve Stice discuss exosomes and how they can be harnessed to treat CNS diseases.